Jubilant Life Sciences Ltd (JULS.NS)
23 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|60||Executive Co-Chairman of the Board, Managing Director|
|62||2015||Non-Executive Chairman of the Board|
|52||Chief Financial Officer, Executive Director - Finance, Director|
|2015||Chief Executive Officer of Jubilant Pharma Limited|
|51||President - Acetyls and Ethanol|
- BRIEF-Jubilant Life Sciences Says Unit Got ANDA Approval For Amantadine Hydrochloride Tablets
- BRIEF-Jubilant Life Sciences Says Unit Got ANDA Approval For Clonidine Hydrochloride Extended-Release Tablets
- BRIEF-India's Jubilant Life Sciences Issues Commercial Papers Worth 900 Mln Rupees
- BRIEF-India's Jubilant Life Sciences Dec Qtr Consol Profit Up 78 Pct
- BRIEF-Jubilant Life Sciences Unit Gets sNDA Approval For New Indications From USFDA For Draximage DTPA